RxDoctor Payments Data

Sarah Phillips

Nurse Practitioner · Tacoma, WANPI 1194377705

Payments from drug & device makers

$504in general payments, 2019–2025

Across 24 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$125
  • Otsuka America Pharmaceutical, Inc.$110
  • Teva Pharmaceuticals USA, Inc.$48
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$44
  • Alkermes, Inc.$39
  • AbbVie$23
  • plus $114 from 6 others

What the payments were for

  • Food & beverage$44087%
  • Education$6513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$504 in reported general payments places this provider in the 80th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$144,867
Medicare patients
349
Services billed
1,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban283$184,587
EliquisApixaban288$176,648
OzempicSemaglutide121$138,900
JardianceEmpagliflozin153$93,848
JanuviaSitagliptin Phosphate140$80,447
XifaxanRifaximin23$79,452
TrulicityDulaglutide68$73,324
MyrbetriqMirabegron116$59,815
Invega SustennaPaliperidone Palmitate20$55,423
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$49,039
Gabapentin1,260$42,317
Spiriva HandihalerTiotropium Bromide67$38,679
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc396$37,732
Atorvastatin Calcium1,779$32,683
Incruse ElliptaUmeclidinium Bromide82$32,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$176,648288 claims
Novo NordiskOzempic, Rybelsus$125$160,812142 claims
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta$16$93,242170 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$44$79,45223 claims
Astellas Pharma US IncMyrbetriq$20$59,815116 claims
AbbVieLinzess, Creon$23$39,98248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →